{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:00:39Z","timestamp":1792166439868,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100032499","name":"Hyperoxalurie Zentrum Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032499","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009579","name":"Oxalosis and Hyperoxaluria Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1053\/j.ajkd.2025.03.023","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T19:11:11Z","timestamp":1747422671000},"page":"236-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Understanding Rare Kidney Stone Diseases: A Review"],"prefix":"10.1053","volume":"86","author":[{"given":"Michelle A.","family":"Baum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.G.","family":"Somers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7257\/1053-816X.2017.37.2.81","article-title":"Early recognition and management of rare kidney stone disorders","volume":"37","author":"Goldstein","year":"2017","journal-title":"Urol Nurs"},{"issue":"10","key":"10.1053\/j.ajkd.2025.03.023_bib2","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2014070698","article-title":"Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.03.023_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/JU.0000000000004147","article-title":"The evolving role of genetic testing in monogenic kidney stone disease: spotlight on primary hyperoxaluria","volume":"212","author":"Breeggemann","year":"2024","journal-title":"J Urol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.023_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1681\/ASN.2014040388","article-title":"Fourteen monogenic genes account for 15% of nephrolithiasis\/nephrocalcinosis","volume":"26","author":"Halbritter","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.023_bib5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.kint.2017.06.025","article-title":"Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis","volume":"93","author":"Daga","year":"2018","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2025.03.023_bib6","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/ckj\/sfab232","article-title":"Treatment of primary hyperoxaluria type 1","volume":"15","author":"Gupta","year":"2022","journal-title":"Clin Kidney J"},{"issue":"11","key":"10.1053\/j.ajkd.2025.03.023_bib7","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1007\/s00467-024-06328-2","article-title":"Diagnosis and management of primary hyperoxalurias: best practices","volume":"39","author":"Michael","year":"2024","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.023_bib8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","article-title":"Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope","volume":"19","author":"Groothoff","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.03.023_bib9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/ndt\/gfab027","article-title":"Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2","volume":"37","author":"Singh","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.023_bib10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.kint.2021.03.031","article-title":"A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3","volume":"100","author":"Martin-Higueras","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2025.03.023_bib11","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.kint.2019.08.018","article-title":"Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up","volume":"96","author":"Garrelfs","year":"2019","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2025.03.023_bib12","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.ekir.2023.07.025","article-title":"Determinants of kidney failure in primary hyperoxaluria type 1: findings of the European Hyperoxaluria Consortium","volume":"8","author":"Metry","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"13","key":"10.1053\/j.ajkd.2025.03.023_bib13","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2025.03.023_bib14","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.03.023_bib15","first-page":"1","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial","volume":"38","author":"Hayes","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.023_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int"},{"issue":"18","key":"10.1053\/j.ajkd.2025.03.023_bib18","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"10.1053\/j.ajkd.2025.03.023_bib19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ekir.2024.02.1439","article-title":"Nedosiran safety and efficacy in PH1: interim analysis of PHYOX3","volume":"9","author":"Groothoff","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.023_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00240-023-01453-3","article-title":"Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)","volume":"51","author":"Goldfarb","year":"2023","journal-title":"Urolithiasis"},{"issue":"6","key":"10.1053\/j.ajkd.2025.03.023_bib21","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/ajt.12706","article-title":"Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant","volume":"14","author":"Lorenz","year":"2014","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ndt\/gfac295","article-title":"Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases","volume":"38","author":"Sellier-Leclerc","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.ajkd.2025.03.023_bib23","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00467-021-05342-y","article-title":"Cystinuria: an update on pathophysiology, genetics, and clinical management","volume":"37","author":"D\u2019Ambrosio","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.023_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.kint.2020.06.035","article-title":"Cystinuria: clinical practice recommendation","volume":"99","author":"Servais","year":"2021","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2025.03.023_bib25","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1089\/end.2019.0703","article-title":"Evaluation and medical management of patients with cystine nephrolithiasis: a consensus statement","volume":"34","author":"Eisner","year":"2020","journal-title":"J Endourol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.03.023_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/00099228221140802","article-title":"Antenatal hyperechogenic colon and cystinuria","volume":"62","author":"Akar","year":"2023","journal-title":"Clin Pediatr"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.023_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pcl.2018.09.003","article-title":"Update on Dent disease","volume":"66","author":"Ehlayel","year":"2019","journal-title":"Pediatr Clin North Am"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/hmg\/8.2.247","article-title":"Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent\u2019s disease","volume":"8","author":"Devuyst","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1053\/j.ajkd.2025.03.023_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fphar.2017.00151","article-title":"ClC Channels and transporters: structure, physiological functions, and implications in human chloride channelopathies","volume":"8","author":"Poroca","year":"2017","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1086\/427887","article-title":"Dent disease with mutations in OCRL1","volume":"76","author":"Hoopes","year":"2005","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.023_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/PGE-2012-005","article-title":"Novel OCRL mutations in patients with Dent-2 disease","volume":"1","author":"B\u00f6ckenhauer","year":"2012","journal-title":"J Pediatr Genet"},{"issue":"4","key":"10.1053\/j.ajkd.2025.03.023_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005058","article-title":"The Lowe syndrome protein OCRL1 is required for endocytosis in the Zebrafish pronephric tubule","volume":"11","author":"Oltrabella","year":"2015","journal-title":"PLoS Genet"},{"issue":"8","key":"10.1053\/j.ajkd.2025.03.023_bib33","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/humu.22804","article-title":"Mutation update of the CLCN5 gene responsible for Dent disease 1","volume":"36","author":"Mansour-Hendili","year":"2015","journal-title":"Hum Mutat"},{"issue":"12","key":"10.1053\/j.ajkd.2025.03.023_bib34","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2215\/CJN.03710416","article-title":"Glomerular pathology in Dent disease and its association with kidney function","volume":"11","author":"Wang","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.03.023_bib35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2215\/CJN.00900207","article-title":"Hypothesis: Dent disease is an underrecognized cause of focal glomerulosclerosis","volume":"2","author":"Copelovitch","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.03.023_bib36","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s00467-009-1299-2","article-title":"Dent\u2019s disease manifesting as focal glomerulosclerosis: is it the tip of the iceberg?","volume":"24","author":"Frishberg","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.kint.2016.04.022","article-title":"Observations of a large Dent disease cohort","volume":"90","author":"Blanchard","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.023_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpeds.2009.01.049","article-title":"Dent-2 disease: a mild variant of Lowe syndrome","volume":"155","author":"B\u00f6kenkamp","year":"2009","journal-title":"J Pediatr"},{"issue":"9","key":"10.1053\/j.ajkd.2025.03.023_bib39","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00467-006-0172-9","article-title":"Hypercalciuria in patients with CLCN5 mutations","volume":"21","author":"Ludwig","year":"2006","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.023_bib40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00439-020-02219-2","article-title":"Genetics and phenotypic heterogeneity of Dent disease: the dark side of the moon","volume":"140","author":"Gianesello","year":"2021","journal-title":"Hum Genet"},{"issue":"5","key":"10.1053\/j.ajkd.2025.03.023_bib41","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/j.1523-1755.2004.00571.x","article-title":"Evidence for genetic heterogeneity in Dent\u2019s disease","volume":"65","author":"Hoopes","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.023_bib42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s40064-015-1294-y","article-title":"Nephrolithiasis, kidney failure and bone disorders in Dent disease patients with and without CLCN5 mutations","volume":"4","author":"Network O behalf of the DDI","year":"2015","journal-title":"SpringerPlus"},{"issue":"8","key":"10.1053\/j.ajkd.2025.03.023_bib43","first-page":"473","article-title":"Dent\u2019s disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance","volume":"87","author":"Wrong","year":"1994","journal-title":"QJM"},{"issue":"4","key":"10.1053\/j.ajkd.2025.03.023_bib44","first-page":"381","article-title":"Nephrolithiasis","volume":"19","author":"Scheinman","year":"1999","journal-title":"Semin Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.03.023_bib45","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00467-016-3499-x","article-title":"Proteinuria in Dent disease: a review of the literature","volume":"32","author":"van Berkel","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.03.023_bib46","article-title":"Phenotypic spectrum and antialbuminuric response to angiotensin converting enzyme inhibitor and angiotensin receptor blocker therapy in pediatric Dent disease","volume":"8","author":"Deng","year":"2020","journal-title":"Mol Genet Genom Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.03.023_bib47","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00467-012-2329-z","article-title":"Hereditary causes of kidney stones and chronic kidney disease","volume":"28","author":"Edvardsson","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.023_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/ajkd.2001.26826","article-title":"Clinical features and genotype of adenine phosphoribosyltransferase deficiency in Iceland","volume":"38","author":"Edvardsson","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2025.03.023_bib49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.2009080808","article-title":"Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency","volume":"21","author":"Boll\u00e9e","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.023_bib50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.ajkd.2015.10.023","article-title":"Kidney disease in adenine phosphoribosyltransferase deficiency","volume":"67","author":"Runolfsdottir","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"2-3","key":"10.1053\/j.ajkd.2025.03.023_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0009-8981(88)90318-X","article-title":"Characterization of an adenine phosphoribosyltransferase deficiency","volume":"172","author":"Chiba","year":"1988","journal-title":"Clin Chim Acta"},{"issue":"8","key":"10.1053\/j.ajkd.2025.03.023_bib52","first-page":"762","article-title":"Child\u2019s urinary lithiasis revealing a complete deficit in adenine phosphoribosyl transferase","volume":"10","author":"Debray","year":"1976","journal-title":"Pediatr Res"},{"issue":"4","key":"10.1053\/j.ajkd.2025.03.023_bib53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00467-011-2037-0","article-title":"Adenine phosphoribosyltransferase deficiency in children","volume":"27","author":"Harambat","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ajkd.2025.03.023_bib54","first-page":"93","article-title":"Corneal dystrophy and total adenine phosphoribosyltransferase (APRT) deficiency","volume":"213","author":"Neetens","year":"1986","journal-title":"Bull Soc Belge Ophtalmol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.03.023_bib55","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/ndt\/gfp711","article-title":"Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure","volume":"25","author":"Nasr","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2025.03.023_bib56","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1111\/ajt.12926","article-title":"Recurrent 2,8-dihydroxyadenine nephropathy: a rare but preventable cause of renal allograft failure","volume":"14","author":"Zaidan","year":"2014","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2025.03.023_bib57","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1097\/TP.0000000000003088","article-title":"Kidney transplant outcomes in patients with adenine phosphoribosyltransferase deficiency","volume":"104","author":"Runolfsdottir","year":"2019","journal-title":"Transplantation"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.023_bib58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00467-018-4109-x","article-title":"Long-term renal outcomes of APRT deficiency presenting in childhood","volume":"34","author":"Runolfsdottir","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1086\/499409","article-title":"SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis","volume":"78","author":"Bergwitz","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"10","key":"10.1053\/j.ajkd.2025.03.023_bib60","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1681\/ASN.2013101085","article-title":"Mutations in SLC34A3\/NPT2c are associated with kidney stones and nephrocalcinosis","volume":"25","author":"Dasgupta","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib61","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-023-01156-2","article-title":"Hereditary hypophosphatemic rickets with hypercalciuria presenting with enthesopathy, renal cysts, and high serum c-terminal FGF23: single-center experience and systematic review","volume":"114","author":"Dodamani","year":"2024","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"10.1053\/j.ajkd.2025.03.023_bib62","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.kint.2023.06.019","article-title":"Rare variants in the sodium-dependent phosphate transporter gene SLC34A3 explain missing heritability of urinary stone disease","volume":"104","author":"Sadeghi-Alavijeh","year":"2023","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2025.03.023_bib63","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13715","article-title":"Clinical, biochemical, and pathophysiological analysis of SLC34A1 mutations","volume":"6","author":"Fearn","year":"2018","journal-title":"Physiol Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib64","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1681\/ASN.2014101025","article-title":"Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia","volume":"27","author":"Schlingmann","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.03.023_bib65","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/clinem\/dgab431","article-title":"Mild idiopathic infantile hypercalcemia\u2014part 1: biochemical and genetic findings","volume":"106","author":"Lenherr-Taube","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1053\/j.ajkd.2025.03.023_bib66","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJMoa1103864","article-title":"Mutations in CYP24A1 and idiopathic infantile hypercalcemia","volume":"365","author":"Schlingmann","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2025.03.023_bib67","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.ekir.2021.04.030","article-title":"High prevalence of kidney cysts in patients with CYP24A1 deficiency","volume":"6","author":"Hanna","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.023_bib68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.ajkd.2014.06.037","article-title":"Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations","volume":"65","author":"Figueres","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.03.023_bib69","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jc.2016-4048","article-title":"CYP3A4 induction by rifampin: an alternative pathway for vitamin D inactivation in patients with CYP24A1 mutations","volume":"102","author":"Hawkes","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2025.03.023_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2023.106301","article-title":"Rifampin monotherapy for children with idiopathic infantile hypercalcemia","volume":"231","author":"Lenherr-Taube","year":"2023","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.03.023_bib71","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/ckj\/sfv028","article-title":"Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole","volume":"8","author":"Sayers","year":"2015","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib72","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpeds.2010.02.025","article-title":"Infantile hypercalcemia and hypercalciuria: new insights into a vitamin D-dependent mechanism and response to ketoconazole treatment","volume":"157","author":"Nguyen","year":"2010","journal-title":"J Pediatr"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.023_bib73","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/ckj\/sfu019","article-title":"Two novel mutations of the CLDN16 gene cause familial hypomagnesaemia with hypercalciuria and nephrocalcinosis","volume":"7","author":"Hanssen","year":"2014","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1053\/j.ajkd.2025.03.023_bib74","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MNH.0000000000000426","article-title":"Claudins and nephrolithiasis","volume":"27","author":"Plain","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"10.1053\/j.ajkd.2025.03.023_bib75","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00467-021-04968-2","article-title":"Familial hypomagnesemia with hypercalciuria and nephrocalcinosis","volume":"36","author":"Vall-Palomar","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"36","key":"10.1053\/j.ajkd.2025.03.023_bib76","doi-asserted-by":"crossref","first-page":"15501","DOI":"10.1073\/pnas.0904411106","article-title":"Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy","volume":"106","author":"Preitner","year":"2009","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"10.1053\/j.ajkd.2025.03.023_bib77","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.3390\/ijms24098455","article-title":"Pathogenic variants of SLC22A12 (URAT1) and SLC2A9 (GLUT9) in Spanish patients with renal hypouricemia: founder effect of SLC2A9 variant c.374C>T; p.(T125M)","volume":"24","author":"Perdomo-Ramirez","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1053\/j.ajkd.2025.03.023_bib78","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ajhg.2008.11.001","article-title":"Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia","volume":"83","author":"Matsuo","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1053\/j.ajkd.2025.03.023_bib79","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ki.2015.28","article-title":"Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management\u2014a KDIGO consensus report","volume":"88","author":"Eckardt","year":"2015","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib80","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11926-011-0231-5","article-title":"Update on the phenotypic spectrum of Lesch-Nyhan disease and its attenuated variants","volume":"14","author":"Torres","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.023_bib81","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00467-006-0267-3","article-title":"Xanthinuria type I: a rare cause of urolithiasis","volume":"22","author":"Arikyants","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.03.023_bib82","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.34067\/KID.0001732021","article-title":"Deletion of Mocos induces xanthinuria with obstructive nephropathy and major metabolic disorders in mice","volume":"2","author":"Sedda","year":"2021","journal-title":"Kidney360"},{"issue":"6","key":"10.1053\/j.ajkd.2025.03.023_bib83","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/ndt\/gfy409","article-title":"Treatment and long-term outcome in primary distal renal tubular acidosis","volume":"34","author":"Lopez-Garcia","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2025.03.023_bib84","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/JU.0000000000004147","article-title":"The evolving role of genetic testing in monogenic kidney stone disease: spotlight on primary hyperoxaluria","volume":"212","author":"Breeggemann","year":"2024","journal-title":"J Urol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.03.023_bib85","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/j.ajkd.2023.03.017","article-title":"Kidney stone pathophysiology, evaluation and management: Core Curriculum 2023","volume":"82","author":"Shastri","year":"2023","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625008650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625008650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:25:32Z","timestamp":1762280732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625008650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0272638625008650"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.03.023","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Rare Kidney Stone Diseases: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}